Five-year data from the KEYNOTE–942 trial show that the personalized mRNA cancer vaccine intismeran autogene, combined with ...

Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this ...

Among patients with advanced melanoma, long-term data have shown that a personalized mRNA cancer vaccine, when combined with the immunotherapy Keytruda (pembrolizumab), has been associated with a 49% ...

A new randomized clinical trial showed that receiving immunochemotherapy infusions earlier in the day may help patients with ...

Pembrolizumab works by blocking a mechanism that cancer cells use to evade detection by the immune system, according to Drugs ...

Feb 4 (Reuters) - Some cancer therapies may be more effective when given earlier in the day, aligning treatment with the body ...

The KEYNOTE-671 trial showed a 71% 36-month overall survival rate with perioperative Keytruda, compared to 64% with placebo. FDA approvals for Keytruda, Imfinzi, and Opdivo in perioperative settings ...

By Michael Erman and Mariam Sunny Feb 3 (Reuters) - Merck & Co on Tuesday forecast 2026 sales and profits below Wall Street estimates, saying the imminent loss of exclusivity on diabetes drug Januvia ...

Merck reported revenue for the fourth quarter was $16.4 billion, an increase of 5% over the fourth quarter of 2024. For the ...

In a landscape defined by rapid change and fierce competition, Merck's recent fourth-quarter earnings report has captured significant attention. The pharmaceutical giant reported earnings and revenue ...